This webinar will provide a detailed look inside Kindeva's state-of-the-art aseptic fill-finish facility. Attendees will learn how Kindeva's advanced capabilities, cutting-edge technology (including the OPTIMA sterile fill finish system) and commitment to progression can streamline the development and manufacturing of injectable drug products. The successful completion of the first registration batches at Bridgeton will also be discussed. The webinar will close by highlighting how Kindeva can act as a strategic partner, helping pharmaceutical companies navigate the complexities of bringing life-saving injectable therapies to market.

This webinar will cover the intricacies of liposomal topical semi-solid products, focusing on their role in enhancing drug delivery through the skin. It will begin with an overview of semi-solid dosage forms, explaining their complex two-phase structure and how liposomes integrate into these formulations.

Key topics will include skin anatomy, drug penetration pathways, and how liposomes improve dermato-pharmacokinetics compared to conventional semi-solid formulations. The session will also explore factors affecting drug release from liposome-based formulations, the influence of flux on skin permeation, and the benefits and challenges of developing these advanced delivery systems. 

In an increasingly complex pharmaceutical landscape, companies face significant challenges in bringing their products from development to market efficiently and seamlessly. The fragmentation of CDMO services, lack of integration between development and manufacturing, and uncertainties in cost and technical feasibility often lead to delays, increased risks, and higher expenses. How can pharmaceutical companies secure a streamlined, reliable, and cost-effective pathway from early development to commercial production?

This webinar aims to answer that question by presenting Fareva’s unique approach as an end-to-end CDMO. With a fully integrated offer, Fareva eliminates the traditional hurdles of fragmented outsourcing by ensuring a seamless transition from pharmaceutical development to industrial-scale manufacturing. Our three GMP pilot sites support product development and technical transfers across fifteen manufacturing facilities, providing a structured and predictable process for our clients. By aligning development and manufacturing from the outset, we simplify project management with a single point of contact, ensure cost visibility, and accelerate time-to-market.

The session will also highlight Fareva’s specialized expertise in high-potency oral solid doses, sterile manufacturing, and biologics, demonstrating how our tailored solutions can support even the most complex pharmaceutical developments. We will explore real-world examples, including how we successfully transferred an mRNA vaccine in record time, overcoming major technical challenges with speed and precision.

Through this presentation, you will gain a clearer understanding of how working with a development-driven CDMO can mitigate risks, optimize resources, and ensure a successful pathway to commercialization.